PubMed · 3626975
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
1987-09-25. Tranexamic acid.. https://pubmed.ncbi.nlm.nih.gov/3626975/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
The drug gevilon that produces hypolipidemic effects has been clinically tested. The drug was used to treat 53 patients suffering from coronary heart disease, hypertensive disease with severe lipid metabolic disturbances. Gevilon has been found to have a hypolipidemic effect in reducing the levels of total cholesterol, beta-cholesterol, triglycerides, increasing alpha-cholesterol levels and normalizing the atherogenicity coefficient. The hypolipidemic effect of the drug is the most pronounced in Type IIb dyslipoproteinemia. Gevilon is well tolerated by patients, it can be used in combination with the drugs given in the complex therapy for coronary heart disease and hypertension.
Today, most upper GI-haemorrhages can be handled without surgery. We discuss the available endoscopic haemostatic methods. Injection therapy seems to be as effective as laser-, heater probe- and bipolar electrocoagulation, and is often preferred because the equipment is inexpensive. In a pilot study of 37 patients with haemorrhage from peptic ulcer (13 with active bleeding and 24 with stigmata of recent hemorrhage) we injected thrombin in the ulcer base and treated the patients systemically with an antifibrinolytic drug (tranexamic acid) for five days. Endoscopic follow-up revealed stigmata of recent haemorrhage in 23 patients on day 1 and in eight patients on day 5. "Blood in stomach" was seen in eight patients on day 1 and in two patients on day 5. Four patients had clinical signs of rebleeding, but only one of them needed operation (definite hemostasis 97%). There were no obvious side effects of the treatment. Contrary to other endoscopic methods, local injection of thrombin does not damage the normal mucosa. However, the method has not been sufficiently explored as yet, and cannot be recommended without strict control and follow-up measures. Early control endoscopy seems to be a sensitive way of monitoring haemostasis.
Explore the source record for details and available documents.